US5576187A - Standards for phosphorothioate insecticide immunoassays - Google Patents

Standards for phosphorothioate insecticide immunoassays Download PDF

Info

Publication number
US5576187A
US5576187A US08/303,343 US30334394A US5576187A US 5576187 A US5576187 A US 5576187A US 30334394 A US30334394 A US 30334394A US 5576187 A US5576187 A US 5576187A
Authority
US
United States
Prior art keywords
compound
standardizing
alkyl
integer
och
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/303,343
Inventor
Fernando M. Rubio
Timothy S. Lawruk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohmicron Technology Inc
Corteva Agriscience LLC
Original Assignee
DowElanco LLC
Ohmicron Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DowElanco LLC, Ohmicron Technology Inc filed Critical DowElanco LLC
Priority to US08/303,343 priority Critical patent/US5576187A/en
Assigned to OHMICRON TECHNOLOGY, INC., DOWELANCO reassignment OHMICRON TECHNOLOGY, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LAWRUK, TIMOTHY S., RUBIO, FERNANDO M.
Application granted granted Critical
Publication of US5576187A publication Critical patent/US5576187A/en
Assigned to PNC BANK DELAWARE reassignment PNC BANK DELAWARE SECURITY AGREEMENT Assignors: STRATEGIC DIANGNOSTICS INC.
Assigned to STRATEGIC DIAGNOSTICS INC. reassignment STRATEGIC DIAGNOSTICS INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: PNC BANK
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/967—Standards, controls, materials, e.g. validation studies, buffer systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds

Definitions

  • the invention relates to improvements in immunoassays for phosphorothioate insecticides, such as chlorpyrifos.
  • Chlorpyrifos and structurally related compounds have insecticidal activity against a variety of arthropods. Because of their extensive use in agriculture, it is important to be able to monitor their levels in water and food that could be ingested by humans. To that end, immunoassays utilizing antibodies against such phosphorothioate compounds as chlorpyrifos, chlorpyrifos-methyl, fenitrothion, and pirimiphos-methyl have been developed (J.H. Skerrit et al, Journal of AOAC International, Vol 75, 519 (1992); J. H. Skerrit et al; abstracts of The 106th AOAC Annual International Meeting & Exposition, Cincinnati, Ohio, 1992. p.162; PCT application PCT/AU90/00278 of J. Skerrit et al).
  • the invention relates to immunoassays involving antibodies that react with chlorpyrifos or compounds structurally related to chlorpyrifos, the inventive improvement being the use of stable compounds as antibody-reactive standards in such assays.
  • stable compounds are diethylchlorothiophosphate, diethyl 4-methylbenzylphosphonate, and N-methyl-3,5,6-trichloro-2-pyridinone, or similar compounds.
  • kits comprising the stable standards.
  • FIG. 1 Immunoassay standardization curves.
  • FIG. 2 Reactivity of N-methyl-3,5,6-trichloro-2-pyridinone in the immunoassay as a function of time and temperature of storage of that compound.
  • FIG. 3 Reactivity of diethyl 4-methylbenzylphosphonate in the immunoassay as a function of time and temperature of storage of that compound.
  • FIG. 4 Reactivity of the compound, diethylchlorothiophosphate, in the immunoassay as a function of time and temperature of storage of that compound.
  • FIG. 5 Reactivity of the compound, chlorpyrifos, in the immunoassay as a function of time and temperature of storage of that compound.
  • the invention is an immunoassay process comprising the steps of:
  • a sample preferably a solution, and more preferably an aqueous solution
  • an antibody reacting a sample (preferably a solution, and more preferably an aqueous solution) with an antibody, said sample comprising an amount of analyte, said antibody reactive against said analyte,
  • step (2) 2) reacting a known amount of a standardizing compound (preferably in solution, and more preferably in an aqueous solution) with an antibody of the same specificity as that used in step (1),
  • step 5) utilizing the amounts quantitated in steps (3) and (4) and the known amount in step (2) to calculate the amount of analyte present in the sample used in step (1), wherein the analyte is ##STR1## wherein the standardizing compound is either ##STR2## wherein X 1 x is C or N,
  • X 2 is C if X l is C
  • X 2 is C or N if X l is N,
  • R is C 1 -C 4 alkyl
  • R 2 is H, C 1 -C 4 alkyl, NO 2 , a dialkylamino that is di(C 1 -C 4 alkyl)amino, Cl, Br, I, (C 1 -C 4 alkyl)--S--, C 1 -C 4 alkyl-(O ⁇ S)--, --SO 2 NH 2 , or --S--R 5 , provided that R 2 is --S--R 5 only if X 1 and X 2 are both C and R 2 is in the para position (4-position on the benzene ring),
  • R 3 is H, Cl, Br, or I
  • R 4 is H, Cl, Br, or I
  • R 5 is ##STR3## wherein R 6 is C 1 -C 4 alkyl
  • R 7 is Cl, Br, I, OH, (CH 2 ), m CH 3 , benzyl or benzyl substituted with I, Cl, Br, CH 3 , OCH 3 , O(CH2) m CH 3 , and m is an integer in the range 1 through 10 (i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10)
  • R 8 is O, NH, or S
  • R 9 is H, or C 1 -C 4 alkyl
  • R 10 is Cl, Br, I, CH 3 , (CH 2 ) q CH 3 , OCH 3 , or O(CH 2 ) q CH 3 , and q is an integer in the range 1 through 10,
  • R 11 is (CH 2 ) y , and y is an integer in the range 1 through 10
  • R 12 is O, NH, or S
  • R 13 is CH 3 , (CH 2 ) z CH 3 ,OCH 3 , or O(CH 2 ) z CH 3 and wherein z is an integer in the range 1 through 10,
  • R 14 is Cl, I or Br,
  • R 15 is H, Cl, Br, or I
  • R 16 is H, Cl, Br, or I
  • R 2 , R 3 , and R 4 are not joined to X 1 if it is N or to X 2 if it is N. Otherwise, the foregoing text and diagrams in this Description section of the application are not intended to limit the positions of the three substituents, R 2 , R 3 , and R 4 , to any particular position or positions on the 6-atom aromatic ring to which they are linked, except that not more than one of those three substituents can be at any given atom on the ring on a single compound, and of course none of those substituents can be at the same position occupied by the --O--PS(OR 1 ) 2 group.
  • the invention is a process of calibrating a standardizing compound relative to a test compound of interest in an immunoassay of interest, said process comprising the steps of:
  • step (2) reacting under the immunoassay conditions of step (1) a known amount of a standardizing compound with an antibody of the same specificity as that used in step (1) (i.e., same immunoassay conditions as step (1) except that the test compound has been replaced with the standardizing compound),
  • test compound is ##STR4## wherein the standardizing compound is either ##STR5## wherein X 1 is C or N,
  • X 2 is C if X 1 is C
  • X 2 is C or N if X 1 is N
  • R 1 is C 1 -C 4 alkyl
  • R 2 is H, C 1 -C 4 alkyl, NO 2 , a dialkylamino that is di(C 1 -C 4 alkyl)amino, Cl, Br, I, (C 1 -C 4 alkyl)--S--, C 1 -C 4 alkyl-(O ⁇ S)--, --SO 2 NH 2 , or --S--R 5 , provided that R 2 is --S--R 5 only if X 1 and X 2 are both C and R 2 is in the para position (4-position on the benzene ring)
  • R 3 is H, Cl, Br, or I
  • R 4 is H, Cl, Br, or I
  • R 5 is ##STR6## wherein R 6 is C 1 -C 4 alkyl
  • R 7 is Cl, Br, I, OH, (CH 2 ) m CH 3 , benzyl or benzyl substituted with I, Cl, Br, CH 3 , OCH 3 , O(CH2) m CH 3 , and m is an integer in the range 1 through 10 (i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10)
  • R 8 is 0, NH, or S
  • R 9 is H or C 1 -C 4 alkyl
  • R 10 is Cl, Br, I, CH 3 , (CH 2 ) q CH 3 , OCH 3 , or O(CH 2 ) q CH 3 , and q is an integer in the range 1 through 10,
  • R 11 is (CH 2 ) y , and y is an integer in the range 1 through 10
  • R 12 is O, NH, or S
  • R 13 is CH 3 , (CH 2 ) z CH 3 , OCH 3 , or O(CH 2 ) z CH 3 and wherein z is an integer in the range 1 through 10,
  • R 14 is Cl, I or Br,
  • R 15 is H, Cl, Br, or I
  • R 16 is H, Cl, Br, or I
  • R 2 , R 3 , and R 4 are not joined to X 1 if it is N or to X 2 if it is N.
  • R 2 is dialkylamino then it be used when X 1 and X 2 are both N and that it be at that carbon on the aromatic ring immediately adjacent to both N atoms.
  • R 2 is NO 2 , C 1 -C 4 alkyl-S--, C 1 -C 4 alkyl-(O ⁇ S)--, --SO 2 NH 2 , that X 1 and X 2 both be C and that R 2 be at the 4-position on the aromatic ring; in those cases it is even more preferred that R 3 and R 4 both be H.
  • Particularly preferred standardizing compounds are N-methyl-3,5,6-trichloro-2-pyridinone, diethyl 4-methylbenzylphosphonate, and diethylchlorothiophosphate.
  • N-methyl-3,5,6-trichloro-2-pyridinone is a compound described above with R 13 and R 14 and wherein R 13 is methyl and R 14 is Cl. It was obtained from DowElanco, Indianapolis, Ind.
  • Diethyl 4-methylbenzylphosphonate is a compound described above with R 9 , R 10 , R 11 , and R 12 , and wherein R 9 is ethyl, R 10 is methyl, R 11 is CH 2 , R 12 is O and R 15 and R 16 are H. It is commercially available from Lancaster Synthesis, Windham, N.H.
  • Diethylchlorothiophosphate is the compound above with R 6 , R 7 , and R 8 , and wherein R 6 is ethyl, R 7 is Cl and R 8 is S. It is commercially available from Aldrich Chemical Company, Milwaukee, Wis.
  • C 1 -C 4 alkyl includes methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, and tert-butyl.
  • An example of "(C 1 -C 4 )alkyl S--" is "--SCH 2 CH 3 ".
  • C 1 -C 4 alkyl-(O ⁇ S)-- the C 1 -C 4 alkyl group is directly linked to the sulfur atom and the sulfur atom is also directly linked to both the oxygen atom and the aromatic ring of the analyte or test compound.
  • R 3 is Cl, Br, or I
  • both R 2 and R 4 are either H, Cl, Br, or I. It is more preferred that if R 3 is Cl, Br, or I, then R 2 , R 3 , and R 4 be the same.
  • R 15 is Cl, Br, or I
  • both R 10 and R 16 are either H, Cl, Br, or I. It is more preferred that if R 15 is Cl, Br, or I, then R 10 , R 15 , and R 16 be the same.
  • Preferred analyte and test compounds are: chlorpyrifos, chlorpyrifos-methyl, diazinon, fenitrothion, parathion-methyl, parathion, fensulfothion, fenthion, pyrimiphos-ethyl, pyrimiphos-methyl, dicapthon, cythioate, and temephos.
  • Chlorpyrifos is O,O-diethyl O-(3,5,6-trichloro-2-pyridyl)phosphorothioate (CAS: 2921-88-2).
  • Chlorpyrifos-methyl is O,O-dimethyl O-(3,5,6-trichloro-2-pyridyl)phosphorothioate. (CAS: 598-13-0).
  • Diazinon is O,O-odiethyl O-isopropyl-6-methylpyfimidin-4-yl phosphorothioate (CAS:333-41-5).
  • Fenitrothion is O,O-dimethyl O-(3-methyl-4-nitrophenyl)phosphorothioate (CAS: 122-14-5).
  • Parathion-methyl is O,O-dimethyl O-4-nitrophenyl phosphorothioate (CAS:298-00-0).
  • Parathion is O,O-diethyl O-4-nitrophenyl phosphorothioate (CAS: 56-38-2).
  • Fensulfothion is O,O-diethyl O-[p-(methylsulfinyl)phenyl]phosphorothioate (CAS: 115-90-2).
  • Fenthion is O,O-dimethyl O-[3-methyl-4(methylthio)phenyl]phosphorothioate (CAS:55-38-9).
  • Pyfimiphos-ethyl is O-2-diethylamino-6-methylpyrimidin-4-yl O,O-diethylphosphorothioate (CAS:23505-41-1).
  • Pyfimiphos-methyl is O-2-diethylamino-6-methylpyfimidin-4-yl O,O-dimethylphosphorothioate (CAS: 29232-93-7).
  • Dicapthon is O(2-chloro-4-nitrophenyl) O,O-dimethyl phosphorothioate (CAS: 2463-84-5).
  • Cythioate is O,O-dimethyl O-p-sulfamoylphenyl phosphorothioate (CAS:115-93-5).
  • a preferred way to do the assay is to first do the assay with a known amount (A c ) of freshly made chlorpyrifos as standardizing compound and also with a known amount (A sc ) of a stable standardizing compound (e.g., diethylchlorothiophosphate), such that the same signal, S, is generated by chlorpyrifos and the stable standardizing compound (e.g., In Example 1 below, the signal is the absorbance at 450 nm).
  • a c a known amount of freshly made chlorpyrifos as standardizing compound
  • a sc a stable standardizing compound
  • the stable standardizing compound e.g., diethylchlorothiophosphate
  • chlorpyrifos were stable under storage, it would not be necessary for purposes of analyzing for chlorpyrifos to also do the assay with a stable standardizing compound other than chlorpyrifos. As shown in Example 1, however, chlorpyrifos is not stable upon storage. Therefore it is better to use a stable standardizing compound (e.g., diethyl 4-methylbenzylphosphonate) as the standard when measuring a sample with unknown amounts of chlorpyrifos.
  • a stable standardizing compound e.g., diethyl 4-methylbenzylphosphonate
  • a related invention is a kit for an immunoassay in which the analyte is ##STR7## said kit comprising a standardizing compound that is either ##STR8##
  • An antibody used in steps (1) and (2) may be a polyclonal or monoclonal antibody. If the antibody is a polyclonal preparation, then in order to use antibodies of the same specificity in both steps (1) and (2), it is preferred that portions of the same aliquot of the preparation are used for steps (1) and (2). If the antibody is a monoclonal antibody generated by a hybridoma, then in order that antibodies of the same specificity be used in steps (1) and (2), it is preferred that antibodies from that hybridoma will be used for steps (1) and step (2).
  • the invention and the standardizing compounds can be used in any assay format: competition assays (as in Example 1 below) where the analyte competes with labeled chlorpyrifos for the binding sites provided by the anti-chlorpyrifos antibody; non-competition assays, where the analyte does not compete for such binding sites; sandwich assays, where one anti-analyte antibody acts as a bridge to bind the analyte to a solid phase, and a second anti-analyte antibody with a detectable label is allowed to attach to the solid phase-bound analyte; or any other immunoassay format.
  • competition assays as in Example 1 below
  • non-competition assays where the analyte does not compete for such binding sites
  • sandwich assays where one anti-analyte antibody acts as a bridge to bind the analyte to a solid phase, and a second anti-analyte antibody with a detectable label
  • Diluted samples should be kept on ice and assayed as soon as possible. All other reagents, including the standards and control, should be at room temperature prior to use. Sample dilutions should be made using Diluent/Zero Standard and mixed thoroughly prior to assaying.
  • Color Reagent is prepared just prior to use by combining 1 volume of Chromogen solution with one volume of Peroxide solution.
  • the Color Reagent is prepared in a clean glass container and should remain clear.
  • the solution of antibody-coupled particles should not be in glass containers.
  • Reagents are added directly to the bottom of a tube while avoiding contact between the reagents in the tube and the pipet tip or droplets attached to the pipet tip. Cross-contamination and carry-over of reagents is avoided by using clean pipers for each sample addition. Foam formation during vortexing is undesirable.
  • a magnetic separator (e.g., the RAPID Magnetic Separator) consists of two parts: an upper rack which securely holds the test tubes and a lower part which contains magnets used to attract the antibody-coupled magnetic particles.
  • the rack is described and illustrated in J.A. Itak et al, Chemosphere, vol 24, pp 11-21 (1992).
  • the rack and the lower part of the separator are combined to pull the magnetic particles to the walls of the tubes. To obtain optimum assay precision, it is important to perform the separation steps carefully and consistently.
  • the rack is decanted by inverting it using a smooth turning action so that the liquid flows consistently along one side of the test tube. While still inverted, the rack is placed on an absorbent pad and allowed to drain. Lifting the rack and replacing gently into the pad several times will ensure complete removal of the liquid from the rim of the tube.
  • the antibody-coupled magnetic particles should be mixed just prior to pipetting.
  • the assay was performed as follows:
  • a 1M glycine solution was then used to quench any unreacted sites for 30 minutes.
  • the particles were then washed four times with 5 ml of 25 mM Tris, 150 mM NaCl, 0.1% BSA, 15 ppm Kathon (octhilinone, Rohm & Haas), 1 mM EDTA, pH 7.4.
  • Particles were diluted so as to achieve an iron concentration of 8-10 mg/ml and stored in 25 mM Tris/150 mM NaCl, 0.1% bovine serum albumin (BSA), 15 ppm Kathon, 1 mM ethylenediaminetetraacetic acid (EDTA), pH 7.4.
  • BSA bovine serum albumin
  • EDTA ethylenediaminetetraacetic acid
  • the magnetic particles were diluted 1:1000 in 150 mM Tris, 150 mM NaCl 0.1% Gel (fish gelatin, Sigma, St. Louis, Mo., Cat #G7765), 15 ppm active Kathon, 1 mM EDTA, pH 7.4.
  • a 1:100,000 dilution of a solution of anti-chlorpyrifos monoclonal antibody serum (21.6 mg/ml of antibody) was added and incubated at room temperature (about 25° C.) for at least 16 hours.
  • Chlorpyrifos enzyme conjugate was chlorpyrifos conjugated to horse radish peroxidase (HRP) and was diluted to a concentration of approximately 18 ng/ml in 25 mM sodium acetate, 150 mM NaCl, 0.1 mM luminol (3-aminophthalhydrazide), 0.1% gel, 15 ppm Kathon, pH 5.0.
  • HRP horse radish peroxidase
  • Each standardizing compound was dissolved or diluted in methanol to obtain a concentration of 10 mg/ml and then diluted to the specified concentration in "Diluent/Zero Standard" (25 mM sodium acetate, 150 mM NaCl, 0.1% gel, 0.1 mM EDTA, 15 ppm Kathon, pH 4.0).
  • Peroxide solution was a 0.02% solution of hydrogen peroxide in citric buffer, pH 4.5. (Obtained from Kirkegaard & Perry Laboratories, Gaithersburg, Md.)
  • Chromogen solution was 0.4 g/ml of 3,3'5,5'tetramethylbenzidine ("TMB") in 26% dimethylformamide. (Obtained from Kirkegaard & Perry Laboratories, Gaithersberg, Md.).
  • Washing Buffer was 25 mM Tris, 150 mM NaCl, 0.1% gel, 0.1% Tween, 15 ppm Kathon, pH 7.4.
  • Polystyrene test tubes were used.
  • Anti-chlorpyrifos antibody was prepared by using a chlorpyrifos-thyroglobulin (porcine) immunogen whose structure is: ##STR9## wherein the amine moiety on the thyroglobulin is contributed by a primary amine of that protein.
  • Balb/c mice were immunized by injecting them subcutaneously with 200 ug of the chlorpyrifos-thyroglobulin immunogen in Freund's complete adjuvant. Three 100 ug subcutaneous injections with Freund's incomplete adjuvant followed, 3, 5 and 6 weeks after initial immunization. Three weeks after the last injection, a 100 ug i.p. injection was given in phosphate buffer saline. Mice were sacrificed, spleens were removed and their cells fused with PEG (polyethylene glycol) to P3X myeloma cells. Following screening and recloning, appropriate hybridomas were grown as ascites tumors in mice.
  • PEG polyethylene glycol
  • step (3) Added 500 uL of magnetic particles coupled to anti-chlorpyrifos antibodies to each tube and vortexed the test tube of step (2).
  • B/Bo o is the absorbance at 450 nm observed for chlorpyrifos or a standardizing compound at that concentration divided by the absorbance at 450 nm observed with zero standard (just "Diluent Standard Buffer" buffer).
  • FIGS. 2, 3, 4, and 5 show the value of B/Bo as a function of how long the chlorpyrifos was stored prior to testing in the assay.
  • the temperature of storage either 50, 37, RT (room temperature), 4, or minus 20° C.
  • the temperature of storage is shown at the right end of each line describing the stability.
  • the concentrations of the various compounds were:
  • Example 1 is performed except that instead of chlorpyrifos, samples with an unknown amount of chlorpyrifos is used.
  • the results (B/Bo) are used to calculate the amount of chlorpyrifos in the sample for those samples that have chlorpyrifos in the chlorpyrifos concentration range tested in FIG. 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Improvements in immunoassays for chlorpyrifos and compounds structurally related to chlorpyrifos are achieved by using standards of increased stability.

Description

This application is a continuation-in-part application of application Ser. No. 8/127,583 filed Sep. 28, 1993, abandoned.
FIELD OF THE INVENTION
The invention relates to improvements in immunoassays for phosphorothioate insecticides, such as chlorpyrifos.
BACKGROUND
Chlorpyrifos and structurally related compounds have insecticidal activity against a variety of arthropods. Because of their extensive use in agriculture, it is important to be able to monitor their levels in water and food that could be ingested by humans. To that end, immunoassays utilizing antibodies against such phosphorothioate compounds as chlorpyrifos, chlorpyrifos-methyl, fenitrothion, and pirimiphos-methyl have been developed (J.H. Skerrit et al, Journal of AOAC International, Vol 75, 519 (1992); J. H. Skerrit et al; abstracts of The 106th AOAC Annual International Meeting & Exposition, Cincinnati, Ohio, 1992. p.162; PCT application PCT/AU90/00278 of J. Skerrit et al).
Normally, in an immunoassay, known quantities of the substance being assayed for; i.e., the analyte, are used as standards to calibrate the assay. Not all phosphorothioate insecticides are stable in aqueous conditions, however. Therefore, it is desirable to have a substance that will both react with antibodies such as anti-chlorpyrifos antibodies and be stable.
BRIEF SUMMARY OF THE INVENTION
The invention relates to immunoassays involving antibodies that react with chlorpyrifos or compounds structurally related to chlorpyrifos, the inventive improvement being the use of stable compounds as antibody-reactive standards in such assays. Examples of such stable compounds are diethylchlorothiophosphate, diethyl 4-methylbenzylphosphonate, and N-methyl-3,5,6-trichloro-2-pyridinone, or similar compounds. Related inventions are kits comprising the stable standards.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1. Immunoassay standardization curves.
FIG. 2. Reactivity of N-methyl-3,5,6-trichloro-2-pyridinone in the immunoassay as a function of time and temperature of storage of that compound.
FIG. 3. Reactivity of diethyl 4-methylbenzylphosphonate in the immunoassay as a function of time and temperature of storage of that compound.
FIG. 4. Reactivity of the compound, diethylchlorothiophosphate, in the immunoassay as a function of time and temperature of storage of that compound.
FIG. 5. Reactivity of the compound, chlorpyrifos, in the immunoassay as a function of time and temperature of storage of that compound.
DESCRIPTION
In one general aspect, the invention is an immunoassay process comprising the steps of:
1) reacting a sample (preferably a solution, and more preferably an aqueous solution) with an antibody, said sample comprising an amount of analyte, said antibody reactive against said analyte,
2) reacting a known amount of a standardizing compound (preferably in solution, and more preferably in an aqueous solution) with an antibody of the same specificity as that used in step (1),
3) quantitating the amount of antibody that reacted with the sample in step (1);
4) quantitating the amount of antibody that reacted with the standardizing compound in step (2);
5) utilizing the amounts quantitated in steps (3) and (4) and the known amount in step (2) to calculate the amount of analyte present in the sample used in step (1), wherein the analyte is ##STR1## wherein the standardizing compound is either ##STR2## wherein X1 x is C or N,
X2 is C if Xl is C,
X2 is C or N if Xl is N,
R is C1 -C4 alkyl,
R2 is H, C1 -C4 alkyl, NO2, a dialkylamino that is di(C1 -C4 alkyl)amino, Cl, Br, I, (C1 -C4 alkyl)--S--, C1 -C4 alkyl-(O═S)--, --SO2 NH2, or --S--R5, provided that R2 is --S--R5 only if X1 and X2 are both C and R2 is in the para position (4-position on the benzene ring),
R3 is H, Cl, Br, or I,
R4 is H, Cl, Br, or I,
R5 is ##STR3## wherein R6 is C1 -C4 alkyl,
R7 is Cl, Br, I, OH, (CH2),m CH3, benzyl or benzyl substituted with I, Cl, Br, CH3, OCH3, O(CH2)m CH3, and m is an integer in the range 1 through 10 (i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10)
R8 is O, NH, or S,
R9 is H, or C1 -C4 alkyl,
R10 is Cl, Br, I, CH3, (CH2)q CH3, OCH3, or O(CH2)q CH3, and q is an integer in the range 1 through 10,
R11 is (CH2)y, and y is an integer in the range 1 through 10
R12 is O, NH, or S,
R13 is CH3, (CH2)z CH3,OCH3, or O(CH2)z CH3 and wherein z is an integer in the range 1 through 10,
R14 is Cl, I or Br,
R15 is H, Cl, Br, or I,
R16 is H, Cl, Br, or I,
provided that R2, R3, and R4, are not joined to X1 if it is N or to X2 if it is N. Otherwise, the foregoing text and diagrams in this Description section of the application are not intended to limit the positions of the three substituents, R2, R3, and R4, to any particular position or positions on the 6-atom aromatic ring to which they are linked, except that not more than one of those three substituents can be at any given atom on the ring on a single compound, and of course none of those substituents can be at the same position occupied by the --O--PS(OR1)2 group. Similarly, the foregoing text and diagrams in this Description section of the application are not intended to limit the positions of the three substituents, R10, R15, and R6, to any particular position or positions on the 6-atom aromatic ring to which they are linked, except that not more than one of those three substituents can be at any given atom on the ring on a single compound, and of course none of those substituents can be at the same position occupied by the --O--R11 PR12 S(OR9)2 group.
In another embodiment, the invention is a process of calibrating a standardizing compound relative to a test compound of interest in an immunoassay of interest, said process comprising the steps of:
1) reacting a known amount of test compound with an antibody,
2) reacting under the immunoassay conditions of step (1) a known amount of a standardizing compound with an antibody of the same specificity as that used in step (1) (i.e., same immunoassay conditions as step (1) except that the test compound has been replaced with the standardizing compound),
3) quantitating the amount of antibody that reacted with the test compound in step (1);
4) quantitating the amount of antibody that reacted with the standardizing compound in step (2);
5) utilizing the amounts quantitated in steps (3) and (4) and the known amounts of steps (1) and (2) to calculate the relative reactivity of the standardizing compound and the test compound under the immunoassay conditions of step (1),
wherein the test compound is ##STR4## wherein the standardizing compound is either ##STR5## wherein X1 is C or N,
X2 is C if X1 is C,
X2 is C or N if X1 is N,
R1 is C1 -C4 alkyl,
R2 is H, C1 -C4 alkyl, NO2, a dialkylamino that is di(C1 -C4 alkyl)amino, Cl, Br, I, (C1 -C4 alkyl)--S--, C1 -C4 alkyl-(O═S)--, --SO2 NH2, or --S--R5, provided that R2 is --S--R5 only if X1 and X2 are both C and R2 is in the para position (4-position on the benzene ring)
R3 is H, Cl, Br, or I,
R4 is H, Cl, Br, or I,
R5 is ##STR6## wherein R6 is C1 -C4 alkyl,
R7 is Cl, Br, I, OH, (CH2)m CH3, benzyl or benzyl substituted with I, Cl, Br, CH3, OCH3, O(CH2)m CH3, and m is an integer in the range 1 through 10 (i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10)
R8 is 0, NH, or S,
R9 is H or C1 -C4 alkyl,
R10 is Cl, Br, I, CH3, (CH2)q CH3, OCH3, or O(CH2)q CH3, and q is an integer in the range 1 through 10,
R11 is (CH2)y, and y is an integer in the range 1 through 10
R12 is O, NH, or S,
R13 is CH3, (CH2)z CH3, OCH3, or O(CH2)z CH3 and wherein z is an integer in the range 1 through 10,
R14 is Cl, I or Br,
R15 is H, Cl, Br, or I,
R16 is H, Cl, Br, or I,
provided that R2, R3, and R4, are not joined to X1 if it is N or to X2 if it is N.
It is preferred that if R2 is dialkylamino then it be used when X1 and X2 are both N and that it be at that carbon on the aromatic ring immediately adjacent to both N atoms.
It is preferred that when R2 is NO2, C1 -C4 alkyl-S--, C1 -C4 alkyl-(O═S)--, --SO2 NH2, that X1 and X2 both be C and that R2 be at the 4-position on the aromatic ring; in those cases it is even more preferred that R3 and R4 both be H.
Particularly preferred standardizing compounds are N-methyl-3,5,6-trichloro-2-pyridinone, diethyl 4-methylbenzylphosphonate, and diethylchlorothiophosphate.
N-methyl-3,5,6-trichloro-2-pyridinone, is a compound described above with R13 and R14 and wherein R13 is methyl and R14 is Cl. It was obtained from DowElanco, Indianapolis, Ind.
Diethyl 4-methylbenzylphosphonate, is a compound described above with R9, R10, R11, and R12, and wherein R9 is ethyl, R10 is methyl, R11 is CH2, R12 is O and R15 and R16 are H. It is commercially available from Lancaster Synthesis, Windham, N.H.
Diethylchlorothiophosphate is the compound above with R6, R7, and R8, and wherein R6 is ethyl, R7 is Cl and R8 is S. It is commercially available from Aldrich Chemical Company, Milwaukee, Wis.
"C1 -C4 alkyl" includes methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, and tert-butyl. An example of "(C1 -C4)alkyl S--" is "--SCH2 CH3 ".
In C1 -C4 alkyl-(O═S)--, the C1 -C4 alkyl group is directly linked to the sulfur atom and the sulfur atom is also directly linked to both the oxygen atom and the aromatic ring of the analyte or test compound.
It is preferred that if R3 is Cl, Br, or I, then both R2 and R4 are either H, Cl, Br, or I. It is more preferred that if R3 is Cl, Br, or I, then R2, R3, and R4 be the same.
It is preferred that if R15 is Cl, Br, or I, then both R10 and R16 are either H, Cl, Br, or I. It is more preferred that if R15 is Cl, Br, or I, then R10, R15, and R16 be the same.
Preferred analyte and test compounds are: chlorpyrifos, chlorpyrifos-methyl, diazinon, fenitrothion, parathion-methyl, parathion, fensulfothion, fenthion, pyrimiphos-ethyl, pyrimiphos-methyl, dicapthon, cythioate, and temephos.
Chlorpyrifos is O,O-diethyl O-(3,5,6-trichloro-2-pyridyl)phosphorothioate (CAS: 2921-88-2).
Chlorpyrifos-methyl is O,O-dimethyl O-(3,5,6-trichloro-2-pyridyl)phosphorothioate. (CAS: 598-13-0).
Diazinon is O,O-odiethyl O-isopropyl-6-methylpyfimidin-4-yl phosphorothioate (CAS:333-41-5).
Fenitrothion is O,O-dimethyl O-(3-methyl-4-nitrophenyl)phosphorothioate (CAS: 122-14-5).
Parathion-methyl is O,O-dimethyl O-4-nitrophenyl phosphorothioate (CAS:298-00-0).
Parathion is O,O-diethyl O-4-nitrophenyl phosphorothioate (CAS: 56-38-2).
Fensulfothion is O,O-diethyl O-[p-(methylsulfinyl)phenyl]phosphorothioate (CAS: 115-90-2).
Fenthion is O,O-dimethyl O-[3-methyl-4(methylthio)phenyl]phosphorothioate (CAS:55-38-9).
Pyfimiphos-ethyl is O-2-diethylamino-6-methylpyrimidin-4-yl O,O-diethylphosphorothioate (CAS:23505-41-1).
Pyfimiphos-methyl is O-2-diethylamino-6-methylpyfimidin-4-yl O,O-dimethylphosphorothioate (CAS: 29232-93-7).
Dicapthon is O(2-chloro-4-nitrophenyl) O,O-dimethyl phosphorothioate (CAS: 2463-84-5).
Cythioate is O,O-dimethyl O-p-sulfamoylphenyl phosphorothioate (CAS:115-93-5).
Temephos O,O,O,',O'-tetramethyl O,O'-thiodi-p-phenylene bis(phosphorothioate) (CAS:3383-96-8).
If the analyte of interest is chlorpyrifos, a preferred way to do the assay is to first do the assay with a known amount (Ac) of freshly made chlorpyrifos as standardizing compound and also with a known amount (Asc) of a stable standardizing compound (e.g., diethylchlorothiophosphate), such that the same signal, S, is generated by chlorpyrifos and the stable standardizing compound (e.g., In Example 1 below, the signal is the absorbance at 450 nm). The assay must be done under conditions where a change in chlorpyrifos concentration will result in a change in signal and a change in the stable standardizing compound concentration will result in a change in signal. If one then takes a sample with an unknown amount of analyte and obtains the same signal as obtained with an amount Asc of stable standardizing compound, then one would conclude that the analyte in the sample is chlorpyrifos in an amount equal to Ac.
If chlorpyrifos were stable under storage, it would not be necessary for purposes of analyzing for chlorpyrifos to also do the assay with a stable standardizing compound other than chlorpyrifos. As shown in Example 1, however, chlorpyrifos is not stable upon storage. Therefore it is better to use a stable standardizing compound (e.g., diethyl 4-methylbenzylphosphonate) as the standard when measuring a sample with unknown amounts of chlorpyrifos.
The foregoing procedures can be used with assays where the analyte is a phosphorothioate compound other than chlorpyrifos.
A related invention is a kit for an immunoassay in which the analyte is ##STR7## said kit comprising a standardizing compound that is either ##STR8##
An antibody used in steps (1) and (2) may be a polyclonal or monoclonal antibody. If the antibody is a polyclonal preparation, then in order to use antibodies of the same specificity in both steps (1) and (2), it is preferred that portions of the same aliquot of the preparation are used for steps (1) and (2). If the antibody is a monoclonal antibody generated by a hybridoma, then in order that antibodies of the same specificity be used in steps (1) and (2), it is preferred that antibodies from that hybridoma will be used for steps (1) and step (2).
Methods for monoclonal and polyclonal antibody production are well known in the art. For example, McAdam et al, J. Agric. Food Chem., vol 40:1466-70 (1992), describes the use of rabbits for the production of polyclonal antibodies against organophosphate insecticides.
The invention and the standardizing compounds can be used in any assay format: competition assays (as in Example 1 below) where the analyte competes with labeled chlorpyrifos for the binding sites provided by the anti-chlorpyrifos antibody; non-competition assays, where the analyte does not compete for such binding sites; sandwich assays, where one anti-analyte antibody acts as a bridge to bind the analyte to a solid phase, and a second anti-analyte antibody with a detectable label is allowed to attach to the solid phase-bound analyte; or any other immunoassay format. Indeed the term "immunoassay" is intended here in a very general sense and is any assay in which an antibody specific for a phosphorothioate analyte of interest is used.
ASSAY GUIDELINES
Diluted samples should be kept on ice and assayed as soon as possible. All other reagents, including the standards and control, should be at room temperature prior to use. Sample dilutions should be made using Diluent/Zero Standard and mixed thoroughly prior to assaying.
"Color Reagent" is prepared just prior to use by combining 1 volume of Chromogen solution with one volume of Peroxide solution. The Color Reagent is prepared in a clean glass container and should remain clear.
The solution of antibody-coupled particles should not be in glass containers.
Reagents are added directly to the bottom of a tube while avoiding contact between the reagents in the tube and the pipet tip or droplets attached to the pipet tip. Cross-contamination and carry-over of reagents is avoided by using clean pipers for each sample addition. Foam formation during vortexing is undesirable.
A magnetic separator (e.g., the RAPID Magnetic Separator) consists of two parts: an upper rack which securely holds the test tubes and a lower part which contains magnets used to attract the antibody-coupled magnetic particles. The rack is described and illustrated in J.A. Itak et al, Chemosphere, vol 24, pp 11-21 (1992). During incubations the upper rack is removed from the lower part of the magnetic separator so that the magnetic particles remain suspended during the incubation. For separation steps, the rack and the lower part of the separator are combined to pull the magnetic particles to the walls of the tubes. To obtain optimum assay precision, it is important to perform the separation steps carefully and consistently. The rack is decanted by inverting it using a smooth turning action so that the liquid flows consistently along one side of the test tube. While still inverted, the rack is placed on an absorbent pad and allowed to drain. Lifting the rack and replacing gently into the pad several times will ensure complete removal of the liquid from the rim of the tube. The antibody-coupled magnetic particles should be mixed just prior to pipetting.
EXAMPLES EXAMPLE 1
The assay was performed as follows:
Attachment of anti-chlorpyrifos antibodies to magnetic particles was done as follows: One ml of a 50 mg/ml suspension of BioMag 4100 amine-terminated particles (Advanced Magnetics, Cambridge, Mass.) were activated with 5% (v/v) glutaraldehyde in 2 ml of 0.01M MES buffer, pH 6 (MES is 2-(N-morpholino)ethanesulfonic Acid) for 3 hours. Unreacted glutaraldehyde was removed by washing four times with 5 ml of 0.01M MES buffer. Goat anti-mouse IgG serum was diluted to an antibody concentration of 5 mg/ml and 1 ml was reacted with the activated magnetic particles by shaking for 16 hours. A 1M glycine solution was then used to quench any unreacted sites for 30 minutes. The particles were then washed four times with 5 ml of 25 mM Tris, 150 mM NaCl, 0.1% BSA, 15 ppm Kathon (octhilinone, Rohm & Haas), 1 mM EDTA, pH 7.4. Particles were diluted so as to achieve an iron concentration of 8-10 mg/ml and stored in 25 mM Tris/150 mM NaCl, 0.1% bovine serum albumin (BSA), 15 ppm Kathon, 1 mM ethylenediaminetetraacetic acid (EDTA), pH 7.4. The magnetic particles (with bound antibody), were diluted 1:1000 in 150 mM Tris, 150 mM NaCl 0.1% Gel (fish gelatin, Sigma, St. Louis, Mo., Cat #G7765), 15 ppm active Kathon, 1 mM EDTA, pH 7.4. To the diluted particles, a 1:100,000 dilution of a solution of anti-chlorpyrifos monoclonal antibody serum (21.6 mg/ml of antibody) was added and incubated at room temperature (about 25° C.) for at least 16 hours.
Chlorpyrifos enzyme conjugate was chlorpyrifos conjugated to horse radish peroxidase (HRP) and was diluted to a concentration of approximately 18 ng/ml in 25 mM sodium acetate, 150 mM NaCl, 0.1 mM luminol (3-aminophthalhydrazide), 0.1% gel, 15 ppm Kathon, pH 5.0.
Each standardizing compound was dissolved or diluted in methanol to obtain a concentration of 10 mg/ml and then diluted to the specified concentration in "Diluent/Zero Standard" (25 mM sodium acetate, 150 mM NaCl, 0.1% gel, 0.1 mM EDTA, 15 ppm Kathon, pH 4.0).
Peroxide solution was a 0.02% solution of hydrogen peroxide in citric buffer, pH 4.5. (Obtained from Kirkegaard & Perry Laboratories, Gaithersburg, Md.)
Chromogen solution was 0.4 g/ml of 3,3'5,5'tetramethylbenzidine ("TMB") in 26% dimethylformamide. (Obtained from Kirkegaard & Perry Laboratories, Gaithersberg, Md.).
"Stopping Solution" was 2M sulfuric acid.
Washing Buffer was 25 mM Tris, 150 mM NaCl, 0.1% gel, 0.1% Tween, 15 ppm Kathon, pH 7.4.
Polystyrene test tubes were used.
Anti-chlorpyrifos antibody was prepared by using a chlorpyrifos-thyroglobulin (porcine) immunogen whose structure is: ##STR9## wherein the amine moiety on the thyroglobulin is contributed by a primary amine of that protein. Balb/c mice were immunized by injecting them subcutaneously with 200 ug of the chlorpyrifos-thyroglobulin immunogen in Freund's complete adjuvant. Three 100 ug subcutaneous injections with Freund's incomplete adjuvant followed, 3, 5 and 6 weeks after initial immunization. Three weeks after the last injection, a 100 ug i.p. injection was given in phosphate buffer saline. Mice were sacrificed, spleens were removed and their cells fused with PEG (polyethylene glycol) to P3X myeloma cells. Following screening and recloning, appropriate hybridomas were grown as ascites tumors in mice.
Assay Procedure:
1) Added 200 uL (microliters) of chlorpyrifos, standardizing compound, or control ("diluent zero standard") to a test tube;
2) Added 250 uL of chlorpyrifos-HRP conjugate 1:70,000 dilution to the test tube of step (1);
3) Added 500 uL of magnetic particles coupled to anti-chlorpyrifos antibodies to each tube and vortexed the test tube of step (2).
4) Incubated the test tube for 15 minutes at room temperature (about 25° C.).
5) Magnetically separated the particles and substances bound thereto from the other contents of the tube; the particle-free solution was decanted and the particles were washed twice with 1 ml of Washing Solution.
6) Added 500 uL of Color Reagent and vortexed the test tube.
7) Incubated the test tube for 20 minutes at room temperature.
8) Read the absorbance at 450 nm using an RPA-I™ photometer.
For graphical display of the results, the quantity B/Bo for a given concentration of chlorpyrifos or standardizing compound was calculated: B/Boo is the absorbance at 450 nm observed for chlorpyrifos or a standardizing compound at that concentration divided by the absorbance at 450 nm observed with zero standard (just "Diluent Standard Buffer" buffer).
The following four samples were tested:
1) chlorpyrifos (a "test compound")
2) diethyl 4-methylbenzylphosphonate (a "standardizing compound")
3) N-methyl-3,5,6-trichloro-2-pyridinone (a "standardizing compound")
4) diethyl chloro thiophosphate (a "standardizing compound")
The results are shown in FIG. 1 where B/Bo is shown as a function of the ppb (parts per billion) of the sample in the assay.
FIGS. 2, 3, 4, and 5, show the value of B/Bo as a function of how long the chlorpyrifos was stored prior to testing in the assay. The temperature of storage, either 50, 37, RT (room temperature), 4, or minus 20° C. The temperature of storage is shown at the right end of each line describing the stability. The concentrations of the various compounds were:
12 ppM, 80 ppM, and 500 ppM for N-methyl-3,5,6-trichloro-2-pyridinone
9 ppM, 50 ppM, and 220 ppM for diethyl 4omethylbenzylphosphonate
10 ppM, and 50 ppM (parts per million) for diethylchlorothiophosphate
0.25 ppB (parts per billion), 1 ppB, and 5 ppB for chlorpyrifos
The results show that diethyl 4-methylbenzylphosphonate, N-methyl-3,5,6-trichloro-2-pyridinone, and diethylchlorothiophosphate, are more stable than chlorpyrifos.
The results also show the following regarding the relative reactivity of chlorpyrifos and the three standardizing compounds: that 1 ppB of chlorpyrifos was equivalent to 50 ppm of diethyl 4-methylbenzylphosphonate, to 8 ppm of diethylchlorothiophosphate, and to 75 ppm of N-methyl-3,5,6-trichloro-2-pyridinone.
EXAMPLE 2
Example 1 is performed except that instead of chlorpyrifos, samples with an unknown amount of chlorpyrifos is used. The results (B/Bo) are used to calculate the amount of chlorpyrifos in the sample for those samples that have chlorpyrifos in the chlorpyrifos concentration range tested in FIG. 1.

Claims (39)

What is claimed is:
1. An immunoassay process comprising the steps of:
1) reacting a sample with an antibody, said sample comprising an amount of analyte, said antibody reactive against said analyte,
2) reacting a known amount of a standardizing compound with an antibody of the same specificity as that used in step (1),
3) quantitating the amount of antibody that reacted with the sample in step (1);
4) quantitating the amount of antibody that reacted with the standardizing compound in step (2);
5) utilizing the amounts quantitated in steps (3) and (4) and the known amount in step (2) to calculate the amount of analyte present in the sample used in step (1),
wherein the analyte is ##STR10## wherein the standardizing compound is either ##STR11## wherein X1 is C or N,
X2 is C if X1 is C,
X2 is C or N if X1 is N,
R1 is C1 -C4 alkyl,
R2 is H, C1 -C4 alkyl, NO2, a dialkylamino that is di(C1 -C4 alkyl)amino, Cl, Br, I, (C1 -C4 alkyl)--S--, C1 -C4 alkyl-(O═S)--,--SO2 NH2, or --S--R5, provided that R2 is --S--R5 only if X1 and X2 are both C and R2 is in the para position (4-position on the benzene ring)
R3 is H, Cl, Br, or I,
R4 is H, Cl, Br, or I,
R5 is ##STR12## wherein R6 is C1 -C4 alkyl,
R7 is Cl, Br, I, OH, (CH2)m CH3, benzyl or benzyl substituted with I, Cl, Br, CH3, OCH3, O(CH2)m CH3, and m is an integer in the range 1 through 10 (i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10)
R8 is O, NH, or S,
R9 is H or C1 -C4 alkyl,
R10 is Cl, Br, I, CH3, (CH2)q CH3, OCH3, or O(CH2)q CH3, and q is an integer in the range 1 through 10,
R11 is (CH2)y, and y is an integer in the range 1 through 10
R12 is O, NH, or S,
R13 is CH3, (CH2)z CH3, OCH3, or O(CH2)z CH3 and wherein z is an integer in the range 1 through 10,
R14 is Cl, I or Br,
R15 is H, Cl, Br, or I,
R16 is H, Cl, Br, or I,
provided that R2, R3, and R4, are not joined to X1 if it is N or to X2 if it is N.
2. The immunoassay process of claim 1 wherein the analyte is chlorpyrifos, chlorpyrifos-methyl, diazinon, fenitrothion, parathion-methyl, parathion, fensulfothion, fenthion, pyrimiphos-ethyl, pyrimiphos-methyl, dicapthon, cythioate, or temephos.
3. The immunoassay process of claim 1 wherein the standardizing compound is selected from the group consisting of N-methyl-3,5,6-trichloro-2-pyridinone, diethyl 4-methylbenzylphosphonate, and diethylchlorothiophosphate.
4. The immunoassay process of claim 3 wherein the standardizing compound is N-methyl-3,5,6-trichloro-2-pyridinone.
5. The immunoassay process of claim 3 wherein the standardizing compound is diethyl 4-methylbenzylphosphonate.
6. The immunoassay process of claim 3 wherein the standardizing compound is diethylchlorothiophosphate.
7. The immunoassay process of claim 2 wherein the standardizing compound is selected from the group consisting of N-methyl-3,5,6-trichloro-2-pyridinone, diethyl 4-methylbenzylphosphonate and diethylchlorothiophosphate.
8. The immunoassay process of claim 7 wherein the standardizing compound is N-methyl-3,5,6-trichloro-2-pyridinone.
9. The immunoassay process of claim 7 wherein the standardizing compound is diethyl 4-methylbenzylphosphonate.
10. The immunoassay process of claim 7 wherein the standardizing compound is diethylchlorothiophosphate.
11. A process of claim 1 wherein R8 is O or S and wherein R12 is O or S.
12. A process of claim 1 wherein R8 is S and wherein R12 is S.
13. A process of claim 11 wherein the standardizing compound is ##STR13##
14. A process of claim 11 wherein the standardizing compound is ##STR14##
15. A process of claim 11 wherein the standardizing compound is ##STR15##
16. A process of claim 11 wherein R13 is CH3, (CH2)z CH3 or OCH3 and wherein R10 is Cl, Br, I, CH3, (CH2)q CH3, OCH3, or O(CH2)CH3, and q is an integer in the range 1 through 10.
17. A process of claim 12 wherein R13 is CH3, (CH2)z CH3 or OCH3 and wherein R10 is Cl, Br, I, CH3, (CH2)q CH3, OCH3, or O(CH2)CH3, and q is an integer in the range 1 through 10.
18. A process of claim 11 wherein R2 is dialkylamino, X1 and X2 are both N atoms, and R2 is adjacent to the carbon on the aromatic ring immediately adjacent to both of said N atoms.
19. A process of claim 11 wherein R2 is NO2, C1 -C4 alkyl-S--, C1-C 4 alkyl-(O═S)--or --SO2 NH2, wherein X1 and X2 are both C, and R2 is at the 4position on the aromatic ring.
20. A process of claim 19 wherein R3 and R4 are both H.
21. A process of claim 11 wherein R3 is Cl, Br, or I, and wherein R2 and R4 are both either H, Cl, Br, or I.
22. A process of claim 21 wherein R2, R3, and R4 are the same.
23. A process of claim 14 wherein R15 is Cl, Br, or I, and both R10 and R16 are either H, Cl, Br, or I.
24. A process of claim 23 wherein R10, R15, and R16 are the same.
25. A process of calibrating a standardizing compound relative to a test compound of interest in an immunoassay of interest, said process comprising the steps of:
1) reacting a known amount of test compound with an antibody,
2) reacting under the immunoassay conditions of step (1) a known amount of a standardizing compound with an antibody of the same specificity as that used in step (1) (i.e., same immunoassay conditions as step (1) except that the test compound has been replaced with the standardizing compound),
3) quantitating the amount of antibody that reacted with the test compound in step (1);
4) quantitating the amount of antibody that reacted with the standardizing compound in step (2);
5) utilizing the amounts quantitated in steps (3) and (4) and the known amounts of steps (1) and (2) to calculate the relative reactivity of the standardizing compound and the test compound under the immunoassay conditions of step (1),
wherein the test compound is ##STR16## wherein the standardizing compound is either ##STR17## wherein X1 is C or N,
X2 is C if X1 is C,
X2 is C or N if X1 is N,
R1 is C1 -C4 alkyl,
R2 is H, C1 -C4 alkyl, NO2, a dialkylamino that is di(C1 -C4 alkyl)amino, Cl, Br, I, (C1 -C4 alkyl)--S--, C1 -C4 alkyl-(O═S)--, --SO2 NH2, or --S--R5, provided that R2 is --S--R5 only if X1 and X2 are both C and R2 is in the para position (4-position on the benzene ring)
R3 is H, Cl, Br, or I,
R4 is H, Cl, Br, or I,
R5 is ##STR18## wherein R6 is C1 -C4 alkyl,
R7 is Cl, Br, I, OH, (CH2)m CH3, benzyl or benzyl substituted with I, Cl, Br, CH3, OCH3, O(CH2)m CH3, and m is an integer in the range 1 through 10 (i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10)
R8 is O, NH, or S,
R9 is H or C1 -C4 alkyl,
R10 is Cl, Br, I, CH3, (CH2)q CH3, OCH3, or O(CH2)q CH3, and q is an integer in the range 1 through 10,
R11 is (CH2)y, and y is an integer in the range 1 through 10
R12 is O, NH, or S,
R13 is CH3, (CH2)z CH3, OCH3, or O(CH2)z CH3 and wherein z is an integer in the range 1 through 10,
R14 is Cl, I or Br,
R15 is H, Cl, Br, or I,
R16 is H, Cl, Br, or I, provided that R2, R3, and R4, are not joined to X1 if it is N or to X2 if it is N.
26. A process of claim 25 wherein R8 is O or S and wherein R12 is O or S.
27. A process of claim 26 wherein R13 is CH3, (CH2)z CH3 or OCH3 and wherein R10 is Cl, Br, I, CH3, (CH2)q CH3, OCH3, or O(CH2)CH3, and q is an integer in the range 1 through 10.
28. The immunoassay process of claim 25 wherein the analyte is chlorpyrifos, chlorpyrifos-methyl, diazinon, fenitrothion, parathion-methyl, parathion, fensulfothion, fenthion, pyrimiphos-ethyl, pyrimiphos-methyl, dicapthon, cythioate, or temephos.
29. The process of claim 25 wherein the standardizing compound is selected from the group consisting of N-methyl-3,5,6-trichloro-2-pyridinone, diethyl 4-methylbenzylphosphonate, and diethylchlorothiophosphate.
30. The process of claim 29 the standardizing compound is N-methyl-3,5,6-trichloro-2-pyridinone.
31. The process of claim 29 wherein the standardizing compound is diethyl 4-methylbenzylphosphonate.
32. The process of claim 29 wherein the standardizing compound is diethylchlorothiophosphate.
33. The immunoassay process of claim 28 wherein the standardizing compound is selected from the group consisting of N-methyl-3,5,6-trichloro-2-pyridinone, diethyl 4-methylbenzylphosphonate, and diethylchlorothiophosphate.
34. The process of claim 33 the standardizing compound is N-methyl-3,5,6-trichloro-2-pyridinone.
35. The process of claim 33 wherein the standardizing compound is diethyl 4-methylbenzylphosphonate.
36. The process of claim 33 wherein the standardizing compound is diethylchlorothiophosphate.
37. A kit for an immunoassay in which the analyte is ##STR19## said kit comprising an antibody reactive against said analyte, said kit further comprising a standardizing compound that is either ##STR20## wherein X1, is C or N,
X2, is C if X1 is C,
X2 is C or N if X1 is N,
R1, C1 -C4 alkyl,
R2 is H, C1 -C4 alkyl, NO2, a dialkylamino that is di(C1 -C4 alkyl)amino, CI, Br, I (C1 -C4 alkyl)--S--, C1 -C4 alkyl-(O═S)--, --SO2 NH2, or --S--R5, provided that R2 is --S--only if X1, and X2 am both C and R2 is in the para position (4-position on the benzene ring)
R3 is H, CI, B r, or I,
R4, is H, Cl, Br, or I,
R5 is ##STR21## wherein R6 is C1 -C4 alkyl,
R7 is Cl, Br, I, OH, (CH2)m CH3, benzyl or benzyl substituted with I, Cl, Br, CH3, OCH3, O(CH2)m CH3, and m is an integer in the range 1 through 10 (i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10)
R8 is O, NH, or S,
R9 is H or C1 -C4 alkyl,
R10 is Cl, Br, I, CH3, (CH2)q CH3, OCH3, or O(CH2)q CH3, and q is an integer in the range 1 through 10,
R11 is (CH2)y, and y is an integer in the range 1 through 10
R12 is O, NH, or S,
R13 is CH3, (CH2)z CH3, OCH3, or O(CH2)z CH3 and wherein z is an integer in the range 1 through 10,
R14 is Cl, I or Br,
R15 is H, Cl, Br, or I,
R16 is H, Cl, Br, or I,
provided that R2, R3, and R4, are not joined to X1 if it is N or to X2 if it is N.
38. A kit of claim 37 wherein R8 is O or S and wherein R12 is O or S.
39. A kit of claim 38 wherein R13 is CH3, (CH2)z CH3 or OCH3 and wherein R10 is Cl, Br, I, CH3, (CH2)q CH3, or O(CH2)CH3, and q is an integer in the range 1 through 10.
US08/303,343 1993-09-28 1994-09-09 Standards for phosphorothioate insecticide immunoassays Expired - Fee Related US5576187A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/303,343 US5576187A (en) 1993-09-28 1994-09-09 Standards for phosphorothioate insecticide immunoassays

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12758393A 1993-09-28 1993-09-28
US08/303,343 US5576187A (en) 1993-09-28 1994-09-09 Standards for phosphorothioate insecticide immunoassays

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12758393A Continuation-In-Part 1993-09-28 1993-09-28

Publications (1)

Publication Number Publication Date
US5576187A true US5576187A (en) 1996-11-19

Family

ID=22430847

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/303,343 Expired - Fee Related US5576187A (en) 1993-09-28 1994-09-09 Standards for phosphorothioate insecticide immunoassays

Country Status (3)

Country Link
US (1) US5576187A (en)
AU (1) AU7722294A (en)
WO (1) WO1995009364A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100423526B1 (en) * 2001-12-28 2004-03-18 이용태 A Process for Preparing Haptens for Immunoassay of Phosphorothioate Pesticides
KR100644205B1 (en) 2005-06-30 2006-11-10 이용태 Haptens and antibodies for the class-specific determination of organophosphorus pesticides and the immunoassay method using the same
CN104262486A (en) * 2014-09-24 2015-01-07 江苏省农业科学院 Hybridoma cell strain FQ-2G3, monoclonal antibody produced by hybridoma cell strain FQ-2G3 and capable of preventing chlorpyrifos-methyl and immunochromatographic test strip
CN107064494A (en) * 2017-04-17 2017-08-18 四川精卫食品检测科技有限公司 A kind of chlopyrifos detects enzyme linked immunological kit

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212155B2 (en) 2008-03-19 2015-12-15 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
US10793515B2 (en) 2008-03-19 2020-10-06 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
US9206143B2 (en) 2008-03-19 2015-12-08 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
CN104267179B (en) * 2014-09-25 2016-09-07 句容市农业技术推广中心 A kind of isochlorothion colloidal gold fast detecting test paper strip and preparation method thereof
CN106290830A (en) * 2016-07-26 2017-01-04 大连民族大学 A kind of based on up-conversion fluorescence nanoparticle quickly immune chromatography test paper detecting fenifrothion and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000294A1 (en) * 1989-06-30 1991-01-10 Commonwealth Scientific And Industrial Research Organisation Monoclonal and polyclonal antibodies and test method for determination of fenitrothion and closely related organophosphates

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000294A1 (en) * 1989-06-30 1991-01-10 Commonwealth Scientific And Industrial Research Organisation Monoclonal and polyclonal antibodies and test method for determination of fenitrothion and closely related organophosphates

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
A. Hill et al., Issued 1992, Journal of Agricultural and Food Chemistry, "Mono- and Polychlonal Antibodies to the Organophosphate Fenitrothion. 2. Antibody Specificity and Assay Performance," vol. 40, pp. 1471-1474.
A. Hill et al., Issued 1992, Journal of Agricultural and Food Chemistry, Mono and Polychlonal Antibodies to the Organophosphate Fenitrothion. 2. Antibody Specificity and Assay Performance, vol. 40, pp. 1471 1474. *
D. McAdam et al., Issued 1992, Journal of Agricultural and Food Chemistry, "Mono- and Polyclonal Antibodies to the Organophosphate Fenitrothion. 1. Approaches to Hapten-Protein Conjugation," vol. 40, pp. 1466-1470.
D. McAdam et al., Issued 1992, Journal of Agricultural and Food Chemistry, Mono and Polyclonal Antibodies to the Organophosphate Fenitrothion. 1. Approaches to Hapten Protein Conjugation, vol. 40, pp. 1466 1470. *
H. Dahn et al., Magnetic Resonance in Chemistry, "NMR of Terminal Oxygen 9*--17 O NMR of the P--O `Double Bond`: Phosphine Oxides, Phosphinates, Phosphonates, Acylphosphonates and Related Compounds,", vol. 30, pp. 1089-1096.
H. Dahn et al., Magnetic Resonance in Chemistry, NMR of Terminal Oxygen 9* 17 O NMR of the P O Double Bond : Phosphine Oxides, Phosphinates, Phosphonates, Acylphosphonates and Related Compounds, , vol. 30, pp. 1089 1096. *
J. Skerritt et al., Issued 1992, Journal of AOAC International, "Enzyme-Linked Immunosorbent Assay for Quantitation of Organophosphate Pesticides: Fenitrothion, Chlorpyrifos-methyl, and Pirimiphos-methyl in Wheat Grain and Flour-Milling Fractions," vol. 75, pp. 519-528.
J. Skerritt et al., Issued 1992, Journal of AOAC International, Enzyme Linked Immunosorbent Assay for Quantitation of Organophosphate Pesticides: Fenitrothion, Chlorpyrifos methyl, and Pirimiphos methyl in Wheat Grain and Flour Milling Fractions, vol. 75, pp. 519 528. *
J. Skerritt et al., Published 1991, American Chemical Society, ACS Symposium Series, "Testing Cereal Products and Samples by Immunoassay," Chapter 11, pp. 124-138.
J. Skerritt et al., Published 1991, American Chemical Society, ACS Symposium Series, Testing Cereal Products and Samples by Immunoassay, Chapter 11, pp. 124 138. *
S u di et al., Issued 1988, Kieler Milchwirtschaftliche Forschungsberichte, Studies on the development of an immuno assay for the group specific detection of the diethyl ester of phosphates, thiophosphates, dithiophosphates and phosphonates, vol. 40, pp. 179 203. *
S udi et al., Issued 1988, Kieler Milchwirtschaftliche Forschungsberichte, "Studies on the development of an immuno assay for the group-specific detection of the diethyl ester of phosphates, thiophosphates, dithiophosphates and phosphonates," vol. 40, pp. 179-203.

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100423526B1 (en) * 2001-12-28 2004-03-18 이용태 A Process for Preparing Haptens for Immunoassay of Phosphorothioate Pesticides
KR100644205B1 (en) 2005-06-30 2006-11-10 이용태 Haptens and antibodies for the class-specific determination of organophosphorus pesticides and the immunoassay method using the same
CN104262486A (en) * 2014-09-24 2015-01-07 江苏省农业科学院 Hybridoma cell strain FQ-2G3, monoclonal antibody produced by hybridoma cell strain FQ-2G3 and capable of preventing chlorpyrifos-methyl and immunochromatographic test strip
CN107064494A (en) * 2017-04-17 2017-08-18 四川精卫食品检测科技有限公司 A kind of chlopyrifos detects enzyme linked immunological kit
CN107064494B (en) * 2017-04-17 2019-12-24 四川精卫食品检测科技有限公司 Enzyme linked immunosorbent assay kit for chlorpyrifos detection

Also Published As

Publication number Publication date
WO1995009364A1 (en) 1995-04-06
AU7722294A (en) 1995-04-18

Similar Documents

Publication Publication Date Title
EP1019724B1 (en) Diagnostic tests and kits for clostridium difficile
US5576187A (en) Standards for phosphorothioate insecticide immunoassays
EP0139389A1 (en) Antiidiotypic monoclonal antibody reagents and immunoassays employing antiidiotypic monoclonal antibody reagents
WO1998045684A9 (en) Methods for concentrating ligands using magnetic particles
EP0767914A1 (en) Antibodies to lipoproteins and apolipoproteins and methods of use thereof
US5185264A (en) Diluent buffer and method for diluting an assay component
EP0699305B1 (en) Methods, agents and kits for detection of organophosphorus compounds
Brustolin et al. Immunoturbidimetric method for routine determinations of apolipoproteins AI and B
US4692330A (en) Process for accelerating antigen-antibody reaction
AU751938B2 (en) Immunoassay reagents and immunoassay method
EP0479834B1 (en) Competitive enzyme assay for determination of phosphothioate insecticides
EP1233269B1 (en) Agent for the removal of turbidity in biological samples
Barton et al. Kinetic and immunochemical studies of a receptor-like protein that binds aromatic hydrocarbons.
US20040053426A1 (en) Method of immunity examination with insoluble carrier particle and reagent therefor
El Guindi et al. An immunoassay for human transferrin
US9541550B2 (en) Method for immunologically measuring soluble LR11
US5017472A (en) Microflotation devices used for immunoassays and cell/molecular fractionation
WO2001088547A2 (en) Standardized oxidized ldl assay
US5397699A (en) Method for stabilizing an alkanol amine buffer used in optical determinations of enzyme activity
AU646738B2 (en) Denatured vehicular proteins to improve enzyme linked immunosorbent assays
Eremin et al. Immunochemical methods for the assays of herbicides of the 1, 3, 5-triazine group
JP2001330616A (en) Method for manufacturing antigen-binding solid phase
CN104090097B (en) Aqueous solution of specificity binding interaction culture medium serving as binding pair
US5780250A (en) Immunoassay standards for polyaromatic hydrocarbon detection
Robison Use of commercially available ELISA kits for detection of foodborne pathogens

Legal Events

Date Code Title Description
AS Assignment

Owner name: DOWELANCO, INDIANA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RUBIO, FERNANDO M.;LAWRUK, TIMOTHY S.;REEL/FRAME:007814/0101

Effective date: 19950202

Owner name: OHMICRON TECHNOLOGY, INC., DELAWARE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RUBIO, FERNANDO M.;LAWRUK, TIMOTHY S.;REEL/FRAME:007814/0101

Effective date: 19950202

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: PNC BANK DELAWARE, DELAWARE

Free format text: SECURITY AGREEMENT;ASSIGNOR:STRATEGIC DIANGNOSTICS INC.;REEL/FRAME:010832/0397

Effective date: 20000505

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20041119

AS Assignment

Owner name: STRATEGIC DIAGNOSTICS INC., DELAWARE

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:PNC BANK;REEL/FRAME:027317/0171

Effective date: 20111202